Japanese Study Group on Pancreaticobiliary Maljunction, Tokushima, Japan.
J Hepatobiliary Pancreat Sci. 2013 Jun;20(5):472-80. doi: 10.1007/s00534-013-0606-2.
Pancreaticobiliary maljunction (PBM) is a congenital anomaly, which can be defined as a union of the pancreatic and biliary ducts located outside off the duodenal wall. We herein investigate clinical features of PBM including as the 2nd report of a Japanese nationwide survey.
During a period of 18 years (from 1990 to 2007), 2,561 patients with PBM were registered at 141 medical institutions in Japan. Among them, eligible patients (n = 2,529) were divided into two groups: adult (n = 1,511) and pediatric patients (n = 1,018). Comparisons of clinical features including associated biliary cancers were performed according to the biliary dilatation (BD), age factor, and time era.
Only one case in pediatric patients with BD combined with a bile duct cancer (0.1 %). In adult patients, the bile duct cancer and the gallbladder cancer was seen in 6.9 and 13.4 % patients with BD and in 3.1 and 37.4 % patients without BD, respectively. In adult patients with BD, the occurrence rates of biliary cancers were increased in latter period (00'-07') compared with former period (90'-99'). The ratio of biliary cancer localization was changed between former and latter period, and the bile duct cancer was increased in latter period (from 5.5 to 9.3 %).
The largest series of PBM were evaluated to clarify the clinical features including the associated biliary cancer in this Japan-nationwide survey. This report could be widely used in the future as a reference data for diagnosis and treatment of PBM.
胰胆管合流异常(PBM)是一种先天性异常,可定义为胰管和胆管在十二指肠壁外结合。我们在此调查了 PBM 的临床特征,包括作为日本全国性调查的第 2 份报告。
在 18 年期间(1990 年至 2007 年),日本 141 家医疗机构共登记了 2561 例 PBM 患者。其中,符合条件的患者(n=2529)分为两组:成人(n=1511)和儿科患者(n=1018)。根据胆管扩张(BD)、年龄因素和时间阶段比较了包括相关胆管癌在内的临床特征。
儿科患者中仅 1 例 BD 合并胆管癌(0.1%)。在成人患者中,BD 患者中胆管癌和胆囊癌的发生率分别为 6.9%和 13.4%,无 BD 的患者分别为 3.1%和 37.4%。在 BD 的成年患者中,后一时期(00'-07')胆管癌的发生率高于前一时期(90'-99')。胆管癌定位的比例在前后期之间发生了变化,后一时期胆管癌的发生率增加(从 5.5%增加到 9.3%)。
在这项日本全国性调查中,对最大的 PBM 系列进行了评估,以阐明包括相关胆管癌在内的临床特征。该报告将来可广泛用作 PBM 的诊断和治疗参考数据。